Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
457
NCT03179878
Safety and Tolerability of SYNB1020-CP-001
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 16, 2017
Completion: Apr 11, 2018
NCT03447730
Safety, Tolerability and Pharmacodynamics of SYNB1020
Phase: Phase 1/2
Start: Mar 19, 2018
Completion: Jul 19, 2019
NCT03516487
Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria
Start: Apr 17, 2018
Completion: Jun 21, 2019
NCT04167137
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Start: Dec 12, 2019
Completion: Dec 9, 2021
NCT04534842
Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria
Phase: Phase 2
Start: Aug 25, 2020
Completion: Oct 7, 2022
NCT04629170
Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
Start: Nov 4, 2020
Completion: Jan 17, 2023
NCT04984525
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
Start: Jul 2, 2021
Completion: Dec 10, 2021
NCT05377112
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
Phase: Early Phase 1
Start: Mar 29, 2022
Completion: Dec 7, 2022
NCT05462132
Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers
Start: Jul 7, 2022
Completion: Nov 27, 2022
NCT05764239
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
Phase: Phase 3
Start: Jul 5, 2023
Completion: Mar 15, 2024